Navigation Links
Teikoku Pharma USA Acquires Travanti Pharma Inc.
Date:5/8/2009

SAN JOSE, Calif., May 8 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body.

The Company has developed a proprietary Wearable Electronic Disposable Drug delivery technology (WEDD(R)) Platform. WEDD is an innovative electronic transdermal (iontophoretic) drug delivery system that is totally self-contained, single-use, portable and disposable. The company has a number of ready to partner clinical projects focused on improving the delivery of therapeutic medications.

The acquisition is part of Teikoku's core strategy to develop transdermal pharmaceutical products by applying drug delivery technology to make administration of medicines safer and/or more effective, more controllable, and in some cases eliminating the need for injection.

"The acquisition of Travanti Pharma broadens Teikoku's Transdermal delivery capabilities and enhances Teikoku pipelines in the areas of pain and CNS," said Masahisa Kitagawa, President and CEO.

"We are very pleased to join forces with Teikoku, a company that understands our business well and has the capabilities to help move several excellent products based upon Travanti's WEDD technology into the marketplace," commented Robert Cohen, President & CEO of Travanti Pharma. "It is gratifying to complete a transaction that benefits Teikoku, as well as Travanti's shareholders and employees."

About Teikoku

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm(R) (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

Teikoku's commitment is to expand transdermal technologies for the benefit of patients and partners. For more information, please visit www.teikokuusa.com


'/>"/>
SOURCE Teikoku Pharma USA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology: